Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEunice MagalhãesSKSteven M. Kornblau

Discussion

Loading...

Member takes

Overview

Observational study shows low janus kinase 2 expression indicates poor overall survival in AML, suggesting targeted therapies may improve outcomes.

Key Points

  • This research aims to explore the prognostic impact of Janus kinase 2 expression levels in acute myelogenous leukemia patients.
  • Measured protein levels using Reverse Phase Protein Arrays in 806 AML samples.
  • Analyzed data using Cox proportional hazards models and comparative statistical tests for outcomes.
  • Categorized patients into high and low expresion groups based on JAK2 protein levels.
  • Patients with low JAK2 expression had worse overall survival and response to therapy compared to high expression.
  • JAK2 high patients performed better with AraC-based chemotherapy, while low expression groups fared poorly with any therapy.
  • Identified histone H3K4 methylation as a significant correlating factor among JAK2 low and mutant patients.

Cite This Study

Magalhães et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9f4https://doi.org/10.1182/blood-2025-3494
View Full Paper
Ask AI
Bookmark
Share